Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular vesicles do not contribute to higher circulating levels of soluble 1 in idiopathic dilated cardiomyopathy

  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Valero, Ana Gámez
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Soler Botija, Carolina
  • Llucià-Valldeperas, Aida
  • Perea Gil, Isaac
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Lupón, Josep|||0000-0002-5601-9611
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Idiopathic dilated cardiomyopathy () is a frequent cause of heart transplantation. Potentially valuable blood markers are being sought, and low-density lipoprotein receptor-related protein 1 (1) has been linked to the underlying molecular basis of the disease. This study compared circulating levels of soluble 1 (1) in patients and healthy controls and elucidated whether 1 is exported out of the myocardium through extracellular vesicles (s) to gain a better understanding of the pathogenesis of the disease. 1 α chain expression was analysed in samples collected from the left ventricles of explanted hearts using immunohistochemistry. 1 concentrations were determined in platelet-free plasma by enzyme-linked immunosorbent assay. Plasma-derived s were extracted by size-exclusion chromatography () and characterized by nanoparticle tracking analysis and cryo-transmission electron microscopy. The distributions of vesicular (9, 81) and myocardial (caveolin-3) proteins and 1 α chain were assessed in fractions by flow cytometry. 1 α chain was preferably localized to blood vessels in compared to control myocardium. Circulating 1 was increased in patients. 9- and 81-positive fractions enriched with membrane vesicles with the expected size and morphology were isolated from both groups. The 1 α chain was not present in these fractions, which were also positive for caveolin-3. The increase in circulating 1 in patients may be clinically valuable. Although s do not contribute to higher 1 levels in , a comprehensive analysis of content would provide further insights into the search for novel blood markers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of new biophysical markers for pathological ventricular remodelling in tachycardia-induced dilated cardiomyopathy

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Jorge, Esther|||0000-0002-2777-0000
  • Dandurand, Jany
  • Nasarre, Laura
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Bornachea, Olga
  • Amorós Figueras, Gerard|||0000-0002-2109-5550
  • Lacabanne, Colette
  • Viladés Medel, David|||0000-0002-3638-9703
  • Leta, Rubén|||0000-0003-4691-381X
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Cinca, Juan|||0000-0003-4819-4265
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Our aim was to identify biophysical biomarkers of ventricular remodelling in tachycardia-induced dilated cardiomyopathy (). Our study includes healthy controls (N = 7) and pigs (N = 10). Molecular analysis showed global myocardial metabolic abnormalities, some of them related to myocardial hibernation in failing hearts, supporting the translationality of our model to study cardiac remodelling in dilated cardiomyopathy. Histological analysis showed unorganized and agglomerated collagen accumulation in the dilated ventricles and a higher percentage of fibrosis in the right () than in the left () ventricle (P = .016). The Fourier Transform Infrared Spectroscopy () 1st and 2nd indicators, which are markers of the myofiber/collagen ratio, were reduced in dilated hearts, with the 1st indicator reduced by 45% and 53% in the and , respectively, and the 2nd indicator reduced by 25% in the . The 3rd indicator, a marker of the carbohydrate/lipid ratio, was up-regulated in the right and left dilated ventricles but to a greater extent in the (2.60-fold vs 1.61-fold, P = .049). Differential scanning calorimetry () showed a depression of the freezable water melting point in ventricles - indicating structural changes in the tissue architecture - and lower protein stability. Our results suggest that the 1st, 2nd and 3rd indicators are useful markers of cardiac remodelling. Moreover, the 2nd and 3rd indicators, which are altered to a greater extent in the right ventricle, are associated with greater fibrosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • van der Meer, Rutger W.
  • Rijzewijk, Luuk J.
  • Smit, Johannes W. A.
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Nasarre, Laura
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Lamb, Hildo J.
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Using in vitro, in vivo and patient-based approaches, we investigated the potential of circulating microRNAs (miRNAs) as surrogate biomarkers of myocardial steatosis, a hallmark of diabetic cardiomyopathy. We analysed the cardiomyocyte-enriched miRNA signature in serum from patients with well-controlled type 2 diabetes and with verified absence of structural heart disease or inducible ischemia, and control volunteers of the same age range and BMI (N = 86), in serum from a high-fat diet-fed murine model, and in exosomes from lipid-loaded HL-1 cardiomyocytes. Circulating miR-1 and miR-133a levels were robustly associated with myocardial steatosis in type 2 diabetes patients, independently of confounding factors in both linear and logistic regression analyses (P < 0.050 for all models). Similar to myocardial steatosis, miR-133a levels were increased in type 2 diabetes patients as compared with healthy subjects (P < 0.050). Circulating miR-1 and miR-133a levels were significantly elevated in high-fat diet-fed mice (P < 0.050), which showed higher myocardial steatosis, as compared with control animals. miR-1 and miR-133a levels were higher in exosomes released from lipid-loaded HL-1 cardiomyocytes (P < 0.050). Circulating miR-1 and miR-133a are independent predictors of myocardial steatosis. Our results highlight the value of circulating miRNAs as diagnostic tools for subclinical diabetic cardiomyopathy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating non-coding RNAs in biomarker-guided cardiovascular therapy, A novel tool for personalized medicine?

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Bär, Christian
  • Fiedler, Jan
  • Couch, Liam S.
  • Brotons, Carlos|||0000-0001-9388-6581
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Thum, Thomas|||0000-0003-4360-1511
Current clinical guidelines emphasize the unmet need for technological innovations to guide physician decision-making and to transit from conventional care to personalized cardiovascular medicine. Biomarker-guided cardiovascular therapy represents an interesting approach to inform tailored treatment selection and monitor ongoing efficacy. However, results from previous publications cast some doubts about the clinical applicability of biomarkers to direct individualized treatment. In recent years, the non-coding human transcriptome has emerged as a new opportunity for the development of novel therapeutic strategies and biomarker discovery. Non-coding RNA (ncRNA) signatures may provide an accurate molecular fingerprint of patient phenotypes and capture levels of information that could complement traditional markers and established clinical variables. Importantly, ncRNAs have been identified in body fluids and their concentrations change with physiology and pathology, thus representing promising non-invasive biomarkers. Previous publications highlight the translational applicability of circulating ncRNAs for diagnosis and prognostic stratification within cardiology. Numerous independent studies have also evaluated the potential of the circulating non-coding transcriptome to predict and monitor response to cardiovascular treatment. However, this field has not been reviewed in detail. Here, we discuss the state-of-the-art research into circulating ncRNAs, specifically microRNAs and long non-coding RNAs, to support clinical decision-making in cardiovascular therapy. Furthermore, we summarize current methodological and conceptual limitations and propose future steps for their incorporation into personalized cardiology. Despite the lack of robust population-based studies and technical barriers, circulating ncRNAs emerge as a promising tool for biomarker-guided therapy.